Phase II Study of Medi-575 an Anti-Platelet-Derived Growth Factor-Alpha Antibody in Patients With Recurrent Glioblastoma
MEDI-575, an immunoglobulin G2Îº monoclonal antibody, selectively binds to platelet-derived growth factor-Î± receptor (PDGFR-Î±) with high specificity. This multicenter, single-arm, open-label, phase II study evaluated the efficacy and safety of MEDI-575 in patients with recurrent glioblastoma. Adults with first recurrence of glioblastoma following surgery, temozolomide, and radiation received MEDI-575 25 mg/kg intravenously over 60 min every 21 days until disease progression or unacceptable toxicity. Six-month progression-free survival rate (PFS-6) was the primary end point; secondary measures included response rate, overall survival (OS), and safety/tolerability. PDGFR-Î± expression was evaluated by immunohistochemistry. Fifty-six patients were enrolled; median age was 56.5 years (range 23€“79), 66 % were male, and 66 % were aged ‰¥65 years. PFS-6 was 15.4 % [90 % confidence interval (CI) 8.1€“24.9]. No complete or partial responses were observed; 23 (41.1 %) patients had stable disease as best response. Median PFS was 1.4 months (90 % CI 1.4, 1.8); median OS was 9.7 months (90 % CI 6.5, 11.8). The most common treatment-related adverse events (AEs) were diarrhea (16 %), nausea (13 %), and fatigue (13 %). Twelve (21 %) patients reported grade ‰¥3 AEs, with hydrocephalus (n = 3), dysphagia (n = 2), and convulsion (n = 2) reported in more than 1 patient. Two patients had treatment-related Grade ‰¥3 AEs of decreased lymphocyte count and asthenia (n = 1 each). Seven patients (13 %) discontinued MEDI-575 owing to AEs. Labeling of PDGFRÎ± in glioblastoma cells and tumor-associated stromal cells was highly variable, with no correlation with PFS. MEDI-575, although well tolerated, had limited clinical activity in recurrent glioblastoma.
Medical Subject Headings
Journal of Neuro-Oncology
Digital Object Identifier (DOI)
Phuphanich, Surasak; Raizer, Jeffrey; Chamberlain, Marc; Canelos, Paola; Narwal, Rajesh; Hong, Shengyan; Miday, Robert; Nade, Minal; and Laubscher, Kevin, "Phase II Study of Medi-575 an Anti-Platelet-Derived Growth Factor-Alpha Antibody in Patients With Recurrent Glioblastoma" (2017). Neurology. 144.